Issued Patents All Time
Showing 1–24 of 24 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12331099 | VEGF antagonist formulations suitable for intravitreal administration | Eric Furfine, Daniel Dix, Kelly Frye | 2025-06-17 |
| 12168036 | Methods for treating angiogenic eye disorders with high doses of VEGF receptor fusion proteins | Saurabh Wadhwa | 2024-12-17 |
| 12077593 | Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies | Daniel Dix, Douglas Kamen, Scott Walsh | 2024-09-03 |
| 11918785 | Devices and methods for overfilling drug containers | Daniel Dix, Douglas Kamen | 2024-03-05 |
| 11732024 | VEGF antagonist formulations suitable for intravitreal administration | Eric Furfine, Daniel Dix, Kelly Frye | 2023-08-22 |
| 11577025 | Devices and methods for overfilling drug containers | Daniel Dix, Douglas Kamen | 2023-02-14 |
| 11103552 | High concentration VEGF receptor fusion protein containing formulations | Saurabh Wadhwa | 2021-08-31 |
| 11098127 | Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies | Daniel Dix, Douglas Kamen, Scott Walsh | 2021-08-24 |
| 11084865 | VEGF antagonist formulations suitable for intravitreal administration | Eric Furfine, Daniel Dix, Kelly Frye | 2021-08-10 |
| 11071780 | Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab | Robert L. Vitti, Kristine A. Erickson, Karen Chu, Stanley Wiegand, Jingtai Cao +3 more | 2021-07-27 |
| 11066458 | VEGF antagonist formulations suitable for intravitreal administration | Eric Furfine, Daniel Dix, Kelly Frye | 2021-07-20 |
| 10464992 | VEGF antagonist formulations suitable for intravitreal administration | Eric Furfine, Daniel Dix, Kelly Frye | 2019-11-05 |
| 10400025 | VEGF antagonist formulations suitable for intravitreal administration | Eric Furfine, Daniel Dix, Kelly Frye | 2019-09-03 |
| 10072086 | Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies | Daniel Dix, Douglas Kamen, Scott Walsh | 2018-09-11 |
| 9914763 | VEGF antagonist formulations suitable for intravitreal administration | Eric Furfine, Daniel Dix, Kelly Frye | 2018-03-13 |
| 9580489 | VEGF antagonist formulations suitable for intravitreal administration | Eric Furfine, Daniel Dix, Kelly Frye | 2017-02-28 |
| 9340594 | VEGF antagonist formulations for intravitreal administration | Eric Furfine, Daniel Dix, Kelly Frye | 2016-05-17 |
| 9173880 | Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies | Daniel Dix, Douglas Kamen, Scott Walsh | 2015-11-03 |
| 8802107 | VEGF antagonist formulations for intravitreal administration | Eric Furfine, Daniel Dix, Kelly Frye | 2014-08-12 |
| 8481046 | VEGF antagonist formulations for intravitreal administration | Eric Furfine, Daniel Dix, Kelly Frye | 2013-07-09 |
| 8092803 | VEGF antagonist formulations for intravitreal administration | Eric Furfine, Daniel Dix, Kelly Frye | 2012-01-10 |
| 7807164 | Lyophilized VEGF antagonist formulations for intravitreal administration | Eric Furfine, Daniel Dix, Kelly Frye | 2010-10-05 |
| 7608261 | VEGF antagonist formulations suitable for intravitreal administration | Eric Furfine, Daniel Dix, Kelly Frye | 2009-10-27 |
| 5986071 | Method for C-terminal degradation of peptides and proteins | John E. Shively | 1999-11-16 |